SB202190 (FHPI)

For research use only. Not for use in humans.

目录号：S1077

CAS No. 152121-30-7

SB202190 (FHPI)是一种有效的p38 MAPK抑制剂，靶向作用于p38α/β，无细胞试验中IC50为50 nM/100 nM，有时用于代替SB 203580研究其在体内对SAPK2a/p38的潜在作用。SB202190 可通过诱导自噬和血红素氧化酶1来抑制内皮细胞的凋亡。SB202190可显著抑制Erastin依赖的铁死亡ferroptosis。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1091.41	现货
25mg	RMB 1189.49	现货
100mg	RMB 3017.14	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的SB202190 (FHPI)发表文献99篇：

Cancer Cell, 2019, 35(5):798-815

PubMed: 31031016 ( click the link to review the publication )

Cancer Discov, 2018, 8(1):74-93

PubMed: 28923912 ( click the link to review the publication )

Nat Biotechnol, 2017, 35(6):577-582

PubMed: 28459450 ( click the link to review the publication )

Nat Biotechnol, 2016, 34(11):1161-1167

PubMed: 27723727 ( click the link to review the publication )

Nat Chem Biol, 2013, 9(7):428-36

PubMed: 23685672 ( click the link to review the publication )

Neoplasia, 2021, 23(1):129-139

PubMed: 33316537 ( click the link to review the publication )

Redox Biol, 2020, 28:101445

PubMed: 32037305 ( click the link to review the publication )

Cell Death Dis, 2020, 11(9):771

PubMed: 32943609 ( click the link to review the publication )

Cells, 2020, 13;9(5) pii: E1209

PubMed: 32414111 ( click the link to review the publication )

Cells, 2020, 28;9(4) pii: E822

PubMed: 32231153 ( click the link to review the publication )

J Neuroinflammation, 2020, 17(1):364

PubMed: 33261639 ( click the link to review the publication )

Aging (Albany NY), 2020, 7;12(9):8221-8240

PubMed: 32379705 ( click the link to review the publication )

Oxid Med Cell Longev, 2020, 2020:6584059

PubMed: 33274004 ( click the link to review the publication )

Cell Discov, 2020, 6:35

PubMed: 32550000 ( click the link to review the publication )

J Cell Mol Med, 2020, 24(5):3203-3216

PubMed: 32053272 ( click the link to review the publication )

Eur J Immunol, 2020, 10.1002/eji.201948363

PubMed: 32022930 ( click the link to review the publication )

Sci Rep, 2020,

PubMed: 32884042 ( click the link to review the publication )

Front Pharmacol, 2020, 11:758

PubMed: 32523533 ( click the link to review the publication )

Chem Biol Interact, 2020, 317:108944

PubMed: 31935364 ( click the link to review the publication )

Int J Environ Health Res, 2020, 10.1080/09603123.2020.1739236

PubMed: 32191530 ( click the link to review the publication )

Ann Surg Oncol, 2020, 10.1245/s10434-020-08790-2

PubMed: 32632882 ( click the link to review the publication )

J Thorac Dis, 2020, 12(7):3764-3773

PubMed: 32802455 ( click the link to review the publication )

J Exp Med, 2020, 217(2)

PubMed: 31753849 ( click the link to review the publication )

J Dev Biol, 2020, 8(3):E12

PubMed: 32660129 ( click the link to review the publication )
Br J Cancer, 2020, 10.1038/s41416-020-0963-y

PubMed: 32606358 ( click the link to review the publication )

Cell Prolif, 2020, e12869

PubMed: 32597573 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2020, 10(4):779-796

PubMed: 32561494 ( click the link to review the publication )

Mol Cell, 2019, 76(6):965-980

PubMed: 31588023 ( click the link to review the publication )

Theranostics, 2019, 9(13):3879-3902

PubMed: 31281520 ( click the link to review the publication )

Cell Death Dis, 2019, 10(10):718

PubMed: 31558705 ( click the link to review the publication )

Cells, 2019, 8(7)

PubMed: 31248002 ( click the link to review the publication )

Cells, 2019, 8(9)

PubMed: 31461951 ( click the link to review the publication )

Mol Oncol, 2019, 13(2):290-306

PubMed: 30422399 ( click the link to review the publication )

Neoplasia, 2019, 22(1):1-9

PubMed: 31751859 ( click the link to review the publication )

J Cell Physiol, 2019, 10.1002/jcp.29305

PubMed: 31612516 ( click the link to review the publication )

Antiviral Res, 2019, 170:104572

PubMed: 31376425 ( click the link to review the publication )

J Cell Mol Med, 2019, 23(2):920-933

PubMed: 30394679 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(4)

PubMed: 30781441 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(10)

PubMed: 31117181 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Sci Rep, 2019, 9(1):19409

PubMed: 31857650 ( click the link to review the publication )

J Pharmacol Exp Ther, 2019, 370(2):219-230

PubMed: 31189728 ( click the link to review the publication )

Life Sci, 2019, 231:116550

PubMed: 31185235 ( click the link to review the publication )

Int J Biochem Cell Biol, 2019, 116:105610

PubMed: 31518663 ( click the link to review the publication )

Mol Immunol, 2019, 111:162-171

PubMed: 31063937 ( click the link to review the publication )

J Biol Eng, 2019, 13:82

PubMed: 31709009 ( click the link to review the publication )

J Biol Eng, 2019, 13:36

PubMed: 31061676 ( click the link to review the publication )

Microb Pathog, 2019, 130:204-212

PubMed: 30885749 ( click the link to review the publication )
Mol Cell, 2018, 71(1):117-128

PubMed: 30008317 ( click the link to review the publication )

Elife, 2018, 7

PubMed: 29595474 ( click the link to review the publication )

Sci Signal, 2018,

PubMed: 29511118 ( click the link to review the publication )

EBioMedicine, 2018, 36:497-507

PubMed: 30190207 ( click the link to review the publication )

Front Immunol, 2018, 9:1051

PubMed: 29896191 ( click the link to review the publication )

Cancer Immunol Immunother, 2018, 67(2):271-283

PubMed: 29090321 ( click the link to review the publication )

Sci Rep, 2018, 8(1):5074

PubMed: 29568077 ( click the link to review the publication )

Stem Cells Int, 2018, 2018:9793845

PubMed: 30693038 ( click the link to review the publication )

Am J Transl Res, 2018, 10(8):2555-2566

PubMed: 30210692 ( click the link to review the publication )

Infect Immun, 2018, 22;86(9):e00233-18

PubMed: 29986890 ( click the link to review the publication )

Eur J Pharmacol, 2018, 838:129-137

PubMed: 30196111 ( click the link to review the publication )

Toxicon, 2018, 155:1-8

PubMed: 30290166 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2018, 5(3):333-352

PubMed: 29552622 ( click the link to review the publication )

J Clin Invest, 2017, 127(1):153-168

PubMed: 27893461 ( click the link to review the publication )

Nat Chem Biol, 2017, 13(1):38-45

PubMed: 27820799 ( click the link to review the publication )

Biomaterials, 2017, 128:44-55

PubMed: 28288348 ( click the link to review the publication )

Aging Cell, 2017, 16(3):575-584

PubMed: 28345297 ( click the link to review the publication )

Free Radic Biol Med, 2017, 104:280-297

PubMed: 28131902 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2017, 323:44-52

PubMed: 28341536 ( click the link to review the publication )

Int J Mol Med, 2017, 39(1):217-222

PubMed: 27878250 ( click the link to review the publication )

Pulm Pharmacol Ther, 2017, 44:61-69

PubMed: 28315487 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2017, 5(2):113-130

PubMed: 29693040 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2017, 4(1):165-182

PubMed: 29204504 ( click the link to review the publication )

Clin Cancer Res, 2016, 10.1158/1078-0432.CCR-15-2242

PubMed: 27297582 ( click the link to review the publication )
Int J Mol Sci, 2016,

PubMed: 27782092 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2016, 303:79-89

PubMed: 27174766 ( click the link to review the publication )

J Cancer, 2016, 7(8):900-9

PubMed: 27313779 ( click the link to review the publication )

J Diabetes Res, 2016, 2016:9073037

PubMed: 27635403 ( click the link to review the publication )

Oncol Rep, 2016, 35(5):3009-17

PubMed: 26986870 ( click the link to review the publication )

Inflamm Res, 2016, 65(3):193-202

PubMed: 26621504 ( click the link to review the publication )

Neurochem Res, 2016, 41(8):1969-81

PubMed: 27068033 ( click the link to review the publication )

Mol Med Rep, 2016, 14(2):1430-8

PubMed: 27278862 ( click the link to review the publication )

Oncotarget, 2016, 7(25):37407-37419

PubMed: 27270648 ( click the link to review the publication )

Tumour Biol, 2016, 37(8):10269-78

PubMed: 26831669 ( click the link to review the publication )

Mol Syst Biol, 2015, 11(3):797

PubMed: 25814555 ( click the link to review the publication )

EBioMedicine, 2015, 2(12):1944-56

PubMed: 26844273 ( click the link to review the publication )

Inflamm Bowel Dis, 2015, 21(3):496-506

PubMed: 25647156 ( click the link to review the publication )

Cell Transplant, 2015, 24(3):573-88

PubMed: 25654487 ( click the link to review the publication )

Nat Commun, 2014, 5:3479

PubMed: 24632940 ( click the link to review the publication )

Cell Rep, 2014, 8(4):1037-48

PubMed: 25127139 ( click the link to review the publication )

Chem Res Toxicol, 2014, 27(9):1575-85

PubMed: 25148906 ( click the link to review the publication )

BMC Cancer, 2014, 14:325

PubMed: ( click the link to review the publication )

Life Sci, 2014, 108(2):63-70

PubMed: 24857982 ( click the link to review the publication )

Int Immunopharmacol, 2014, 24(1): 50-58

PubMed: 25479727 ( click the link to review the publication )

J Cell Biochem, 2014, 115(5):874-88

PubMed: 24375433 ( click the link to review the publication )

Cell Transplant, 2014, 23(4-5):641-56

PubMed: 24816456 ( click the link to review the publication )

Mol Biosyst, 2014, 10(3):605-12

PubMed: 24413303 ( click the link to review the publication )

Mol Cell Biochem, 2014, 397(1-2):131-8

PubMed: 25138701 ( click the link to review the publication )
Anticancer Agents Med Chem, 2014, 14(8):1154-60

PubMed: 24934165 ( click the link to review the publication )

PLoS One, 2013, 8(9):e73548

PubMed: 24019927 ( click the link to review the publication )

J Biol Chem, 2010, 285(43):32824-33

PubMed: 20729213 ( click the link to review the publication )

产品安全说明书

p38 MAPK抑制剂选择性比较

生物活性

产品描述

特性

SB 202190 与SB 203580极为相似。

靶点

Ferroptosis ^[11] ()	p38α ^[1] (Cell-free assay)	p38β ^[1] (Cell-free assay)
	50 nM	100 nM

体外研究

SB 202190显著抑制内源本底和和抗Fas抗体诱导的MAPKAPK 2活性，且抑制效果呈剂量依赖性。SB 202190本身就足以诱导Jurkat细胞和Hela细胞的死亡：通过激活CPP 32样半胱氨酸蛋白酶，可阻断Bcl - 2的表达。p38β可减轻而p38α可加剧由SB 202190诱导的细胞凋亡^[2]。在HaCaT细胞中SB 202190强烈抑制由紫外线诱导的cox - 2蛋白表达和 mRNA水平^[3]。用SB 202190处理肾小管上皮细胞（正常大鼠k肝脏-52E），可将由白蛋白引发的炎症（单核细胞趋化蛋白-1，MCP - 1）或肿瘤生长因子β-1（TGFβ-1）引发的原纤维化（原骨胶原I a1，procollagen-i alpha1）相关基因降低50%^[4]。SB 202190处理A549细胞，可诱导JNK磷酸化（该磷酸化效应呈时间和剂量依赖性）、转录因子ATF - 2磷酸化，并增加AP – 1与DNA的结合^[6]。SB 202190处理促进THP-1和MV4-11细胞的生长。SB 202190可提高c-Raf 和ERK（细胞外信号调节激酶）磷酸化，暗示由SB 202190诱导的白血病细胞增殖过程有Ras-Raf-MEK-mitogen激活的MAPK通路的参与^[7]。

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
HCT-116	MVnGeY5kfGmxbjDBd5NigQ>?	NH7TdnAzPSEQvF2=	NYnpcGs3OzBibXnu	NUTQSmRvTE2VT9Mg	NGmye2tifHSnboXheIV{KHSqZTDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36gc4YhcEKGLUKgbY4hemW\|cH;ud4l3\SC2bzDERS=>	MlLBNlYzOjN{NUG=
MDA-MB-231	MV3GeY5kfGmxbjDBd5NigQ>?	MUiyJO69VQ>?	MnLBNlQhcA>?		Ml75cIV{e2WwZYOgR2NNOiCrbnT1Z5Rqd25iYomgWG5H\|rF?	MoDiNlYyODB6NEi=
rBMSCs	M2jiVWZ2dmO2aX;uJGF{e2G7	NFvSbpkyOCEQvF2=	NVWyXHd[Oi53IHi=		NXvyeJN1\GWycnXzd4V{KHSqZTDwbI9{eGixconsZZRqd25ib3[gSXJMKGGwZDDwN\|g>	NV3D[WFQOjZyNUOyOlY>
MG63	MW\GeY5kfGmxbjDBd5NigQ>?	MnuyNVAwOjBxM{Cg{txO	NUnhWZlwOjRiaB?=		MXzzbYdvcW[rY3HueIx6KGSnY4LlZZNmeyC2aHWgcIV3\Wxib3[gdIhwe3Cqb4L5cIF1\WRicEO4JIlv\HWlZXSgZpkhS2SFbEKgbY4h[SClb37j[Y51emG2aX;uJE1l\XCnbnTlcpQhdWGwbnXy	M1Sx[VI2QTl6M{Gy
MG63	NXfGdmM{SXCxcITvd4l{KEG\|c3H5	NYHTNohxOTBxMkCvN\|Ah\|ryP	MlfONlQhcA>?		NEnjOIR{cWewaX\pZ4FvfGy7IHTlZ5Jm[XOnZDD0bIUh[XCxcITvd4l{KHKjdHWgc4YhVUd4MzDpcoR2[2WmIHL5JGNlS2x{	NYXXOnJWOjV7OUizNVI>
HTSMCs	MX\GeY5kfGmxbjDBd5NigQ>?	NFLkN3ExNjFxMT:xNEDPxE1?	NEnJcXAyKGh?		NUDodGpxcW6qaXLpeIVlKEORUl2tNk1qdmS3Y3XkJGhQNTFicILveIVqdiCuZY\lcJMh[W6mIH3SUmEh\XiycnXzd4lwdg>?	NHTMZpgzPTl{MUS2OC=>
MIA PaCa-2	MVHGeY5kfGmxbjDBd5NigQ>?	M1q5clIxyqEQvF2=	MUCyOEBp		MYDy[YR2[2WmIHzhZ5RifGViYXPjeY12dGG2aX;uJIlvKGOxbXLpcoF1cW:wIIfpeIgh[m:2aDCyMWRIKGGwZDDEMYFtdG:\|ZdMg	NVPIW5FLOjV6OEi0PFk>
MIA PaCa-2	M{TLVGZ2dmO2aX;uJGF{e2G7	MUOyNOKh\|ryP	MVSyOEBp		NETIeJpz\XO3bITzJIlvKGFibX;k[ZN1KGmwaHnibZRqd25ib3[gTGlHNTIQsTDwdo91\WmwIHHjZ5VufWyjdHnvci=>	NYDDWIM2OjV6OEi0PFk>
BxPC-3	NEPreW5HfW6ldHnvckBCe3OjeR?=	MX6yNOKh\|ryP	NYK4W3A4OjRiaB?=		NIPv[YJz\XO3bITzJIlvKGFibX;k[ZN1KGmwaHnibZRqd25ib3[gTGlHNTIQsTDwdo91\WmwIHHjZ5VufWyjdHnvci=>	M1TNT\|I2QDh6NEi5
AsPC-1	Mn3kSpVv[3Srb36gRZN{[Xl?	NUTNXndEOjEEoN88US=>	NFjlU3gzPCCq		NXThOHc6emW\|dXz0d{BqdiCjIH3v[IV{fCCrbnjpZol1cW:wIH;mJGhKTi1zzsGgdJJwfGWrbjDhZ4N2dXWuYYTpc44>	MW[yOVg5QDR6OR?=
MIA PaCa-2	NVrkN5V4TnWwY4Tpc44hSXO\|YYm=	M3ryfFIxyqEQvF2=	NH3pXWkzPCCq		MWXlcohidmOnczDjcIVifmGpZTDv[kBRSVKSIIfo[Y4h[2:vYnnu[YQhf2m2aDDncJVkd3OnIHHuZYxw\3N?	NFrHfpkzPTh6OES4PS=>
MIA PaCa-2	NU\TTZVZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFPjNIszOMLizszN	MVqyJIg>		NG\te4x{\W6\|aYTpfoV{KGOnbHygcIlv\XNidH:geJJm[XSvZX70JJdqfGhiMj3ES{BidmRiRD3hcIxwe2V?	MYGyOVg5QDR6OR?=
BxPC-3	M2juT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3vvRVIxyqEQvF2=	NG\6T2YzKGh?		M2\mcJNmdnOrdHn6[ZMh[2WubDDsbY5meyC2bzD0doVifG2nboSge4l1cCB{LVTHJIFv\CCGLXHscI9{\Q>?	MoXmNlU5QDh2OEm=
AsPC-1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWCyNOKh\|ryP	MV[yJIg>		MYHz[Y5{cXSrenXzJINmdGxibHnu[ZMhfG9idILlZZRu\W62IIfpeIghOi2GRzDhcoQhTC2jbHzvd4U>	M2PWbVI2QDh6NEi5
HEY	MknUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn[xNlDDqM7:TR?=	NFPnXXUzKGh?		NVvwe41pe2Wwc3n0bZpmeyClZXzsJIxqdmW\|IITvJJRz\WG2bXXueEB4cXSqIEKtSGch[W6mIFStZYxtd3On	MkGyNlU5QDh2OEm=
OVCAR-3	NHPnSYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVPo[HR5OjEEoN88US=>	M1;JZVIhcA>?		Mnrqd4Vve2m2aYrld{Bk\WyuIHzpcoV{KHSxIITy[YF1dWWwdDD3bZRpKDJvRFegZY5lKERvYXzsc5Nm	NUfD[ldrOjV6OEi0PFk>
SK-OV-3	NVHQVmh2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYKyNOKh\|ryP	MYWyJIg>		NVP1UVVQe2Wwc3n0bZpmeyClZXzsJIxqdmW\|IITvJJRz\WG2bXXueEB4cXSqIEKtSGch[W6mIFStZYxtd3On	MUWyOVg5QDR6OR?=
MH7A	MkPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NX60cHlDOjRiaB?=		MXjy[Ylv\m:{Y3XzJJRp\SCrbnjpZol1d3K7IHXm[oVkfHNib3[gXGFP	NFvuPZozPTh4Mkm2Oi=>
MH7A	MkmxRZBweHSxc3nzJGF{e2G7	NF;rNmkzPSEQvF2=	M3PNeVI1KGh?		NIm1d4Rz\X[ncoPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBqdmS3Y3XkJIJ6KFiDTjDhcoQh[2G3c3XkJIFxd3C2b4Ppd{Bw\iClZXzsd{B3cWFiYXP0bZZifGmxbjDv[kBLVkt?	NE[3[4IzPTh4Mkm2Oi=>
SCC25	MmnaSpVv[3Srb36gRZN{[Xl?	M{f4NVIxKM7:TR?=	NUXiZ\|JIOjRiaB?=		M2LocIlv[3KnYYPld{BifXSxcHjh[5khdGW4ZXy=	NYfKZZN4OjV6M{S0NFA>
HaCaT	NHnwOXpHfW6ldHnvckBCe3OjeR?=	MX61JOK2VQ>?	MmqyNlQhcA>?		NYC3UWVwcW6qaXLpeJMhUU[QLd8zMYlv\HWlZXSgR2NNOjJicILv[JVkfGmxbjDs[ZZmdHN?	MYGyOVg{PDN3Mx?=
HaCaT	MknQSpVv[3Srb36gRZN{[Xl?	M1;UbFUhyrWP	NYLZV\|BVOjRiaB?=		MVvpcohq[mm2czDJSm4u\|rFvaX7keYNm\CCFQ1yyNkBxem:mdXP0bY9vKGyndnXsdy=>	M1vkcFI2QDN2M{Wz
HPAEpiCs	NGfVW3pHfW6ldHnvckBCe3OjeR?=	MmDSNU8{NzFyIN88US=>	M1i0elEhcA>?		MWjy[YR2[2W\|IGOxVE1qdmS3Y3XkJGlESU1vMTDwdo91\WmwIHHu[EBuWk6DIHX4dJJme3Orb36gZY5lKHC{b33veIVzKGGldHn2bZR6	MViyOVc{PDlyMB?=
HPAEpiCs	MkfmSpVv[3Srb36gRZN{[Xl?	Ml[0NU8{NzFyIN88US=>	NVyx[5B1OSCq		M1Pr[4lvcGmkaYTzJHMyWC2\|dHnteYxifGWmIFHreEBxcG:\|cHjvdplt[XSrb36gJOKh	MlzUNlU4OzR7MEC=
HPAEpiCs	NFPqPYNHfW6ldHnvckBCe3OjeR?=	NUP4XXlpOS9\|L{GwJO69VQ>?	M2HiblEhcA>?		MXXpcohq[mm2czDTNXAhfGmvZT3k[ZBmdmSnboTsfUB{fGmvdXzheIVlKGNvSoXuJJBpd3OyaH;yfYxifGmxbh?=	NF\B[FgzPTd\|NEmwNC=>
K562	NXL5THNCTnWwY4Tpc44hSXO\|YYm=	MUixNOKh\|ryP	NIjWNG0yyqCq	MV;EUXNQ	NHjDfWdqdmirYnn0d{ByfWmwYXPybY5mNWmwZIXj[YQheDN6IF3BVGsheGixc4Doc5J6dGG2aX;u	MWOyOVY5PDB2Mx?=
PANC-1	NVzGTZE2TnWwY4Tpc44hSXO\|YYm=	NGPkfIwyOCEQvF2=	NXrHeohwOSCq		MVnlcohidmOnczD0bIUh[XW2b4DoZYdq[yCnZn\lZ5TDqA>?	MnTxNlU3OzJ{MkK=
BxPC-3	MWfGeY5kfGmxbjDBd5NigQ>?	NWHITZRYOTBizszN	NY\ZO3VWOSCq		NYT5TFZC\W6qYX7j[ZMhfGinIHH1eI9xcGGpaXOg[YZn\WO2wrC=	MW[yOVY{OjJ{Mh?=
K562	MkK5SpVv[3Srb36gRZN{[Xl?	MlO3NE4zPS1zIN88US=>	MlXQNlQhcA>?		Ml3nd5VxeHKnc4Pld{Bz\XO4ZYLheJJwdC2rbnT1Z4VlKEh{QWigdIhwe3Cqb4L5cIF1cW:w	MYWyOVYyQTN7Mh?=
THP-1	Mnf0SpVv[3Srb36gRZN{[Xl?	NULWTIFKPSEEtV2=	M2PaPVIhcA>?		MWDzbYdvcW[rY3HueIx6KGG2dHXueYF1\XNic3XjdoV1cW:wIH;mJGlNNTIQsTDpcoR2[2WmIHL5JFI4V0iFaH;sJJBtfXNiRmPMMVHDqA>?	NXXKT\|lLOjV3OUi2OlE>
WB	NI\6fpdHfW6ldHnvckBCe3OjeR?=	M3XxTFIx6oDLzszNxsA>	NVzQTJU{OzEkgJntbY4>		M1\OUYRm[3KnYYPld{B1cGViTGDTMUBweiCOVFGtbY5lfWOnZDDJUE03KGGwZDDUUmYu\|rIEoIDyc4R2[3Srb36=	MmDXNlU2OzB4OEK=
RAW 264.7	NVfEbGsxTnWwY4Tpc44hSXO\|YYm=	NI\WfYEyOMLizszN	NFr5e5M{OOLCiX3pci=>		MnTJbY5lfWOnczDjbIFz[WO2ZYLpd5Rq[yC4YXP1c4xifGmxbjDv[kBQS3QEoB?=	NF\yTYgzPTR4MUO5PS=>
RAW 264.7	NYn3XZJDTnWwY4Tpc44hSXO\|YYm=	MmH3NVDDqM7:TR?=	NXP0[ZhYOzEkgJntbY4>		NI\lTYVifHSnboXheIV{KHSqZTDl[oZm[3S\|IH;mJG9RTyCxbjDvd5Rmd2OuYYP0JJJmfHKjY4Tpc44>	NUnIXWdIOjV2NkGzPVk>
HaCaT	NV7TOI5wTnWwY4Tpc44hSXO\|YYm=	Ml\wOFDDqM7:TR?=	MnH2N{0zPCCq	NFL1dGlFVVOR	M2i1SpJm\HWlZYOgeIhmKGGlY4XteYxifGmxbjDv[kBbVy1z	NYfHVGg4OjV2M{W0PFU>
H9c2	NWfPO3BMTnWwY4Tpc44hSXO\|YYm=	MmDPOVDDqM7:TdMg	Mn\qNVIhcA>?		NIC5RpRz\WS3Y3XzJGxFUCC{ZXzlZZNmKGGwZDDNUXAhdG:\|cx?=	MkL6NlUzPDV6MUi=
HSCs	MnTjRZBweHSxc3nzJGF{e2G7	MonFNlUh\|ryP	NHewelQzPMLiaB?=		MVjzbYdvcW[rY3HueIx6KGG2dHXueYF1\XNiVFetbY5lfWOnZDDhZ5RqfmG2ZXSgTHNEeyCjcH;weI9{cXN?	NV\rZ3FVOjR7NkG5OVA>
THP-1	NV23eFBYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MofDO\|IhcA>?	MnywSG1UVw>?	MUPJR\|UxRTRwN988US=>	M{PMTFI1QDF3MEi3
MDDCs	NH3me2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M1;GUVczKGh?	NUXNWVhETE2VTx?=	MmPVTWM2ODJwN988US=>	NUfDOo13OjR6MUWwPFc>
MDDCs	MUfGeY5kfGmxbjDBd5NigQ>?	MWGwMVE2KM7:TR?=	MYm0PEBp	NWWwR\|BHTE2VTx?=	M1nJNZN2eHC{ZYPz[ZMhUU[QLd8xJIFv\CCLUD2xNEBxem:mdXP0bY9vyqB?	M4HUO\|I1QDF3MEi3
MDDCs	NFPl[5hHfW6ldHnvckBCe3OjeR?=	M2rESFAuOTVizszN	M4PYXFQ5KGh?	M{ewfGROW09?	NFT1bYJqdmirYnn0d{BOUVBvMXGsJG1KWC1zYjDhcoQhWkGQVFXTJJBzd2S3Y4Tpc44>	NVnMfFVMOjR6MUWwPFc>
MDDCs	MVnGeY5kfGmxbjDBd5NigQ>?	NGWwTpQyOCEQvF2=	NGf5eGI{NjViaB?=	M13iWmROW09?	MW\icI9kc3NiRVLPWkBIWCxiYoX0JI5wfCCYU2[gS{Bu\WSrYYTl[EBmdnS{eTDpcpRwKGi3bXHuJG1FTEO\|	Mk\iNlQ5OTVyOEe=
macrophages	MoO4SpVv[3Srb36gRZN{[Xl?	NFGwXVgy6oDLzszN	Mn[xOE426oDLaB?=		M2DLdINwdXCuZYTlcJkhcW6qaXLpeJMhVVRvSVnJMYlv\HWlZXSgZYN1cX[jdHnvckBw\iCQRj5OvmI>	M37MRVI1QDB6NkOz
PDL	M2PXUGZ2dmO2aX;uJGF{e2G7	M4r2XVIxyqEQvF5CpC=>	NX7tUJhFOzBibXnu	NEjxSlNFVVOR	M3m0W5Nq\26rZnnjZY51dHliaX7obYJqfHNidHjlJJRmdnOrbHWg[o9z[2VvbXXkbYF1\WRiQl3QMVIh\XiycnXzd4lwdg>?	NGTHZ5ozPDV4MUC4NS=>
AGS	MYrGeY5kfGmxbjDBd5NigQ>?	Mkj6OUDPxE1?	M1voUFMxKG2rbh?=		NH\jdI1{fXCycnXzd4V{yqBzLXnu[JVk\WRiY3HzdIF{\S16IHHu[EBk[XOyYYPlMVMh[WO2aY\heIlwdg>?	M3n2clI1PTR5OEe4
H520	MlK3SpVv[3Srb36gRZN{[Xl?	NYPpXpNmOTEEoNM1US=>	MX:xJIg>	NILLRnlFVVOR	MYjk[YNz\WG\|ZYOgeIhmKHCnbXX0doV5\WRvaX7keYNm\CCPU1iyJI1TVkFiYX7kJJBzd3SnaX6gcIV3\Wy\|	MoTwNlQ2OzB2N{W=
H1703	NGjOdmlHfW6ldHnvckBCe3OjeR?=	NXfW[Go2OTEEoNM1US=>	NGXz[G8yKGh?	MorUSG1UVw>?	NVft[lRZ\GWlcnXhd4V{KHSqZTDw[Y1mfHKneHXkMYlv\HWlZXSgUXNJOiCvUl7BJIFv\CCycn;0[YlvKGyndnXsdy=>	M2DpelI1PTNyNEe1
H520	NHnGbGtHfW6ldHnvckBCe3OjeR?=	NEi2cJEyOMLiwsXN	NI\pd2oyOiCq	NG\WdWxFVVOR	NWTnfZo6cW6qaXLpeJMheGWvZYTy[Zhm\C2nbHnjbZRm\CCPU1iyJJBzd3SnaX6gd5Ri[mmuaYT5	NVPCW2VtOjR3M{C0O\|U>
H1703	MWLGeY5kfGmxbjDBd5NigQ>?	NY\ZbnZFOTEEoNM1US=>	M1P3OlEzKGh?	Mnr3SG1UVw>?	NE[2ZnJqdmirYnn0d{Bx\W2ndILlfIVlNWWuaXPpeIVlKE2VSEKgdJJwfGWrbjDzeIFjcWyrdIm=	NIT6cnEzPDV\|MES3OS=>
H520	NGHKfmFHfW6ldHnvckBCe3OjeR?=	MojKNVDDqML3TR?=	NGPxXoY3KGh?	M4DFTmROW09?	NXnlZY1ke2mpbnnmbYNidnSueTDpcoNz\WG\|ZYOgeIhmKGyndnXsd{Bw\iC3YnnxeYl1cW5vY3;ubpVo[XSnZDDNV2gzKGmwIIDlcYV1emW6ZXSteJJm[XSnZNMgZ4VtdCCuaX7l	NWjxc4U3OjR3M{C0O\|U>
H1703	M3v4UWZ2dmO2aX;uJGF{e2G7	MXqxNOKhyrWP	Ml;JOkBp	M4HOeWROW09?	MUTzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyC2aHWgcIV3\Wy\|IH;mJJVjcXG3aYTpck1kd26sdXfheIVlKE2VSEKgbY4heGWvZYTy[Zhm\C22cnXheIVlyqClZXzsJIxqdmV?	NH\iWVYzPDV\|MES3OS=>
MC3T3-E1	NVXzTXhSTnWwY4Tpc44hSXO\|YYm=	NFnqXpQxNjNxMz:zNEDPxE1?	NVfnPHpYOSCq		M1zFN4F1fGWwdXH0[ZMhXE6ILd8xMYlv\HWlZXSgUW1RNTliZYjwdoV{e2mxbjDpckBiKGOxbnPlcpRz[XSrb36t[IVx\W6mZX70JI1idm6nctMg	MX:yOFUxOjZ7Nh?=
MC3T3-E1	MWjGeY5kfGmxbjDBd5NigQ>?	MXmzNEDPxE1?	MkjiNUBp		MVfheJRmdnWjdHXzJHRPTi4QsT3zeIlufWyjdHXkJJA{QCCPQWDLJJBpd3OyaH;yfYxifGmxbh?=	MmqzNlQ2ODJ4OU[=
HUVECs	MmnESpVv[3Srb36gRZN{[Xl?	MmnLNVDDqML3TR?=	MlrXNUBp		NUS0WZc1cW6qaXLpeJMhXE6ILd8xMYlv\HWlZXSgR3hEVDFicILv[JVkfGmxbh?=	M{PKNVI1PDh5OU[0
AGS	NUTibWp3TnWwY4Tpc44hSXO\|YYm=	NVuze2NkOTEEoNM1US=>	NHnyb2U{OMLibXnu		MV\pcohq[mm2czDJUE0y\|rJvaX7keYNm\CCjY4TpeoF1cW:wIH;mJJA{QA>?	M2jxOVI1PDd7Nkix
MKN-45	NUjIeXJnTnWwY4Tpc44hSXO\|YYm=	Ml;rNVDDqML3TR?=	NUfXZYx6OzEEoH3pci=>		MWPpcohq[mm2czDJUE0y\|rJvaX7keYNm\CCjY4TpeoF1cW:wIH;mJJA{QA>?	NIfvWoozPDR5OU[4NS=>
AGS	MWnGeY5kfGmxbjDBd5NigQ>?	M2PpVFExyqEEtV2=	NXPzU4prOzEEoH3pci=>		MoHWZZR1\W63YYTld{BKVC1zzsKtbY5lfWOnZDDHRUBk\WyuIH3p[5JifGmxbjDhcoQhcW64YYPpc44>	MnHRNlQ1Pzl4OEG=
MKN-45	NYfiZXpmTnWwY4Tpc44hSXO\|YYm=	NXvpVJJDOTEEoNM1US=>	NIjoUnU{OMLibXnu		NX;GRYlH[XS2ZX71ZZRmeyCLTD2x{tIucW6mdXPl[EBISSClZXzsJI1q\3KjdHnvckBidmRiaX72ZZNqd25?	NETvWGMzPDR5OU[4NS=>
AGS	M2e5N2Z2dmO2aX;uJGF{e2G7	Mn;WNVDDqML3TR?=	NYXF[m83OzEEoH3pci=>		MlXSd4lodmmoaXPhcpRtgSCmZXPy[YF{\XNiSXytNe6zNWmwZIXj[YQhVU2SMjDhcoQhVU2SOTDtVm5CKGW6cILld5Nqd25?	NVqwUY9yOjR2N{m2PFE>
MKN-45	M1zjdmZ2dmO2aX;uJGF{e2G7	MUKxNOKhyrWP	NHvXdYY{OMLibXnu		NVjKTVhke2mpbnnmbYNidnSueTDk[YNz\WG\|ZYOgTYwuOc7{LXnu[JVk\WRiTV3QNkBidmRiTV3QPUBuWk6DIHX4dJJme3Orb36=	NH3oPWYzPDR5OU[4NS=>
DCs	MleySpVv[3Srb36gRZN{[Xl?	MknoNlDDqM7:TR?=	NFPueYgyyqCq		MkPV[IVkemWjc3XzJGlNNTF{IIDyc4R2[3Srb36=	MVOyOFQ{PDZ\|Nh?=
HUVEC	NYjhTFMxTnWwY4Tpc44hSXO\|YYm=	MmH1NlAh\|ryvwrC=	Mn;QOUBp	NE[wTGJFVVOR	MXvy[YR2[2W\|IHP5eI9scW6nIHX4dJJme3Orb36gcIV3\Wy\|IHnuJIEh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgcYFvdmW{	NGLFSJEzPDF6OUC2Ni=>
A 549	MXHGeY5kfGmxbjDBd5NigQ>?	MUm1NEDPxE1?	NHT0bGoyKGh?		MW\k[YNz\WG\|ZYOgeIhmKGyndnXsJI9nKEmOLUlCpC=>	Mn:zNlQyPzl4OEi=
H520	M1T3fGZ2dmO2aX;uJGF{e2G7	MVG1M\|ExKM7:TR?=	NFL6Oo0yKGh?	NV7jNlZ6TE2VTx?=	MWTk[YNz\WG\|ZYOgUXNJOiCycn;0[YlvKGG\|IIflcIwh[XNibWLORUBt\X[nbIOgbY4h\2WoaYTpcoljNWW6cH;z[YQh[2WubB?=	NFrSVVMzPDF\|OEmwNy=>
H1703	Mnu2SpVv[3Srb36gRZN{[Xl?	MnHhOU8yOCEQvF2=	NInVS24yKGh?	M1H3SWROW09?	M{HKOYRm[3KnYYPld{BOW0h{IIDyc5RmcW5iYYOge4VtdCCjczDtVm5CKGyndnXsd{BqdiCpZX\peIlvcWJvZYjwc5Nm\CClZXzs	NUfHTGxQOjRzM{i5NFM>
H520	MX;GeY5kfGmxbjDBd5NigQ>?	MWWxNOKhyrWP	NULsNHExOTJiaB?=	NW\wXnU6TE2VTx?=	NGTJeWtl\WO{ZXHz[ZMhVVOKMjDtVm5CKGGwZDDwdo91\WmwIIP0ZYJqdGm2eTDpckBo\W[rdHnubYIufHKnYYTl[EBPW0OOQzDj[Yxtew>?	MljCNlQyOzh7MEO=
H1703	NX3OcJlJTnWwY4Tpc44hSXO\|YYm=	NXXI[o96OTEEoNM1US=>	MWOxNkBp	NUfncVJZTE2VTx?=	M1X6fYRm[3KnYYPld{BOW0h{IH3SUmEh[W6mIIDyc5RmcW5ic4ThZoltcXS7IHnuJIdm\mm2aX7pZk11emWjdHXkJG5US0yFIHPlcIx{	M3u2fFI1OTN6OUCz
MCF-7	M{nObmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXHiRZo6OTEEoN88US=>	MU[yOOKhcA>?		NIPQS\|BqdmirYnn0d{B1cGViQ2KxNFgucW6mdXPl[EBk\WyuIHTlZZRp	MljKNlQyOjh6NUO=
HPAEpiCs	NYG3WY5xTnWwY4Tpc44hSXO\|YYm=	NYPwWFZpOC5zL{GvNVAh\|ryP	NYroUFMzOSCq		MnTZbY5pcWKrdIOgWG5HNc7zLXnu[JVk\WRiY2DMRVLDqHC{b4TlbY4h[W6mIH3SUmEh\XiycnXzd4lwdg>?	NX;4[5NnOjRyNkmxOVg>
podocytes	MlvsSpVv[3Srb36gRZN{[Xl?	MWqxNOKh\|ryP	MYixJIg>		Mm\rbY5pcWKrdIOgWGdH\|rJzLXnu[JVk\WRiYXP0bZZifGmxbjDv[kBxOziPQWDLJIFv\CCHcnuxM\|LDqA>?	NI\sNVYzPDB\|NkKxNi=>
MCF-7	MnjhSpVv[3Srb36gRZN{[Xl?	M{nm[FExyqEQvF2=	MlvINUBp	NXzqfZR{TE2VTx?=	MUDy[YR2[2W\|IITo[UBYSS2rbnT1Z4VlKHCqb4PwbI9zgWyjdHXkJJA{QCCPQWDL	MoLhNlQxOTlyOUC=
MCF-7	MUjGeY5kfGmxbjDBd5NigQ>?	MXyxNOKh\|ryP	NIj6eGozPCCq	MX\EUXNQ	MXXpcoNz\WG\|ZYOgeIhmKFeDLXnu[JVk\WRiYYDvdJRwe2m\|	MYKyOFAyQTB7MB?=
HAPI	MUXGeY5kfGmxbjDBd5NigQ>?	MWixNE8zOC92MNMg{txO	MUixJIg>		NVmxcHc4cW6qaXLpeJMhXEOGRD3pcoR2[2WmIICzPE9LVktiTVHQT{BxcG:\|cHjvdplt[XSrb36=	NIPZVmQzOzl4OUGyNC=>
HAPI	MUXGeY5kfGmxbjDBd5NigQ>?	MlTjNlDDqM7:TdMg	NIWyUXkyKGh?	MmHwSG1UVw>?	NYjLcWhT[XS2ZX71ZZRmeyCWQ1TEMYlv\HWlZXSgZYN1cX[jdHnvckBw\iCrTl;TJIFv\CCycn;keYN1cW:w	NXjKRVBKOjN7NkmxNlA>
HepG2	MYrGeY5kfGmxbjDBd5NigQ>?	MV[zOVAhdk1?	NHHXUnIzPCCq		Mm\pbY5pcWKrdIOgeIhmKGSnZ4XlcIlvNWmwZIXj[YQh[WO2aY\heIlwdiCxZjDwN\|hOSVCN	MVOyN\|k{OzF7OB?=
AGS	NHeyS5JHfW6ldHnvckBCe3OjeR?=	NE\OW4EyOMLizszN	NH7z[FY{OCCvaX6=		MoPlbY5pcWKrdIOgZ4F{eGG\|ZT2zJIFkfGm4YYTpc44h[W6mIHnubIljcXSrb36gc4YhTVKN	M3PHW\|I{QDVyOUm0
HepG2	NWPBS5g5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MonKNE02OCEQvF2=	NEHDcng1QCCq		MkG4bY5pcWKrdIOgeIhmKHC{b3zp[oVz[XSrb36gbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK=	M37CZ\|I{QDB5NUC4
BEL7404	NYHLO3l7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX7Jb4trOC13MDFOwG0>	M3vrdFQ5KGh?		NYL5UlczcW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44hcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI>	NFPhblIzOzhyN{WwPC=>
HL7702	NEjFUpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXLre2JJOC13MDFOwG0>	MUC0PEBp		MmXjbY5pcWKrdIOgeIhmKHC{b3zp[oVz[XSrb36gbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK=	MUOyN\|gxPzVyOB?=
HepG2	Mm\DSpVv[3Srb36gRZN{[Xl?	M4PFdVAuPTBizszN	M4j0elI1KGh?		M4Lk[olvcGmkaYTzJJRp\SCyaH;zdIhwenmuYYTpc44hd2ZicEO4JIRwf26\|dILlZY0heHKxdHXpcpMhVUGSS1HQT\|ItKEGWRkKsJG1UUzFiYX7kJGhUWDJ5IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	MlvoNlM5ODd3MEi=
BEAS-2B	NHjCVo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3PsdlExKM7:TR?=	Mm[0N\|AhdWmw		Mn\pdoV3\XK\|ZYOgeIhmKGSnY4LlZZNmKG:oIHPlcIwhfmmjYnnsbZR6KGmwZIXj[YQh[nliSFPJ	M3XZSFI{Pzh2MEO0
BEAS-2B	MnzSR5l1d3SxeHn0fUBCe3OjeR?=	NGSw[JEyOCEQvF2=	MlHqN\|AhdWmw		NHvGUXBqdmirYnn0[YQhfGinIHnuZ5Jm[XOnIHnuJGxFUCCjbnSgTWwuQCCneIDy[ZN{cW:w	MofvNlM4QDRyM{S=
BEAS-2B	M{j6WWZ2dmO2aX;uJGF{e2G7	NUfZOYdrOTBizszN	M1T2TVMxKG2rbh?=		NXrHc41Q\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[gZ4F{eGG\|ZT2zMEBD[WRiYX7kJIZiew>?	Ml\TNlM4QDRyM{S=
H9c2	MUHGeY5kfGmxbjDBd5NigQ>?	M2DJOFAvODFxMD6xM\|Eh\|ryP	MYOxJIg>		MVrheJRmdnWjdHXzJHRPTi4QsT3pcoR2[2WmIF3NVE06KGW6cILld5Nqd25uIH3SUmEhdGW4ZXzzMEBidmRicILvcY91\XJiYXP0bZZqfHl?	NUXoepNWOjN5N{SyOVI>
H9c2	MnHMSpVv[3Srb36gRZN{[Xl?	NFr6XlYyKM7:TR?=	NFr3XGQyKGh?		NFzJOWZz\WS3Y3XzJHRPTi4QsTDkbZJm[3SueTDzeIlufWyjdHXkJJA{QCCPQWDLJJBpd3OyaH;yfYxifGmxbh?=	MYOyN\|c4PDJ3Mh?=
U937	MmnqSpVv[3Srb36gRZN{[Xl?	NVHGNnZFOTEEoN88UeKh	M3PZN\|EhcA>?		MUnhZpJw\2G2ZYOgeIhmKGOjZn\lbY5mKGWoZnXjeEBwdiCPS2CtNUBidmRiUGCyRYPPuSCvUl7BJJRz[W6\|Y4LpdJRqd26jbDDs[ZZmdHN?	MnHlNlM4ODd\|OEe=
U937	NWTZRnBUTnWwY4Tpc44hSXO\|YYm=	M{njdFExyqEQvF5CpC=>	MknQNUBp		MX7hZpJw\2G2ZYOgZ4Fn\mWrbnWtbY5lfWOnZDDNT3AuOSCmb4fuMZJm\3WuYYTpc44h[W6mIGDQNmFk\|rFidYCtdoVofWyjdHnvci=>	MYOyN\|cxPzN6Nx?=
U937	MkHMSpVv[3Srb36gRZN{[Xl?	NYPMe4YyOTEEoN88UeKh	NIDOcGwyKGh?		MkXTd5VxeHKnc4Pld{BkNUq3bjDhcoQhS1KHQjDwbI9{eGixconsZZRqd25iaX6gZ4Fn\mWrbnWteJJm[XSnZDDj[Yxte8Li	Mkn3NlM4ODd\|OEe=
A549	NEDD[IZHfW6ldHnvckBCe3OjeR?=	NXLBXpZCOC5\|L{OvN\|Ah\|ryP	NFv5bmIyKGh?		Mmjsd4lodmmoaXPhcpRtgSCjdITlcpVifGW\|IFHUVO6{Wy2vZXTpZZRm\CCFT2itNkBxem:2ZXnuJIFv\CCvUl7BJIV5eHKnc4Ppc44h[W6mIIDyc41wfGW{IHHjeIl3cXS7wrC=	MVeyN\|Y5ODZ5NB?=
A549	NHLhR\|RHfW6ldHnvckBCe3OjeR?=	NXLaeFhzOTEEoN88UeKh	NEDlNVExNTNyIH3pci=>		MmXPbY5pcWKrdIOgRXRR\|rOVIHnu[JVk\WRicESyM5A1PCCPQWDLJIFv\CCyM{igUWFRUyCyaH;zdIhwenmuYYTpc44>	NUTmflZPOjN4OEC2O\|Q>
A549	NXnTV\|k{TnWwY4Tpc44hSXO\|YYm=	NXfhc4Q6OTEEoN88UeKh	NHrLcVUyKGh?		NHzIXnRqdmirYnn0d{BCXFEQs2OgbY5lfWOnZDDOSk3PwkJicE[1JJN2[nWwaYSgdIhwe3Cqb4L5cIF1cW:wIHHu[EBPTi4QulKgdJJwdW:2ZYKgZYN1cX[rdIm=	M{XaN\|I{PjhyNke0
A549	NETTfFFHfW6ldHnvckBCe3OjeR?=	M1jPcVExyqEQvF5CpC=>	NFvnUGIyKGh?		NHuwZ5pz\WS3Y3XzJGFVWM7\|Uz3zeIlufWyjdHXkJINRVEF{IIDoc5NxcG:{eXzheIlwdsLi	NGfI[28zOzZ6ME[3OC=>
A549	MX;GeY5kfGmxbjDBd5NigQ>?	MVGxNOKh\|ryPwrC=	NX3QWFdFOSCq		Mn\odoVlfWOnczDBWHDPu1NvZX7oZY5k\WRiZX76fY1ifGmlIHHjeIl3cXS7IH;mJINRVEF{wrC=	NVT3SG1pOjN4OEC2O\|Q>
PC12	M{O3[2Z2dmO2aX;uJGF{e2G7	NXTnSpo{OTBxMkCvOFAh\|ryP	M2L1cVHDqGh?		NVrzSZB3cW6qaXLpeJMhUk6NIHHu[EBxOzh?	NF\zTGEzOzV6NEO1Oy=>
HK-2	NVLwe4VtSXCxcITvd4l{KEG\|c3H5	M3zLRlIxyqEQvF2=	NVvQeYdJOjRiaB?=		Ml\SbY5pcWKrdIOgSXJMKGGwZDDwN\|hOSVCN	Mn;pNlM2PDNzNUG=
H9c2	NUjESVdNTnWwY4Tpc44hSXO\|YYm=	Mn;iNeKh\|ryP	NX[wdZlNOSCq		M1T3b5Jm\HWlZYOgWG5HNc7zLXnu[JVk\WRiTV3QMVkhdVKQQTDs[ZZmdHNiYX7kJJBzd22xdHXyJIFkfGm4aYT5	MlHFNlM{PTN4OUm=
H9c2	M2fqXWZ2dmO2aX;uJGF{e2G7	MnWzNeKh\|ryP	MXSxJIg>		NYfGNZF1emWmdXPld{BVVkZvzsGt[Y5p[W6lZXSgRXAuOSCycn;tc5RmeiCjY4Tpeol1gQ>?	NX;JcllPOjN\|NUO2PVk>
H1650	MYjGeY5kfGmxbjDBd5NigQ>?	NELaOXoyOMLizszNxsA>	MUmxJIg>	MkWxSG1UVw>?	M1H4doRm[3KnYYPld{Bjd3SqIIDyc5RmcW5iYX7kJI1TVkFibHX2[Yx{KG:oIFXSR2MyKGmwIIDhZ4xqfGG6ZXyt[Zhxd3OnZNMgZ4VtdHN?	M4jL[\|I{OjJ6Nkm2
H1703	M3;5eWZ2dmO2aX;uJGF{e2G7	NE\VPWsyOMLizszNxsA>	NVH3ell[OSCq	NVfDdZZ4TE2VTx?=	Mn2z[IVkemWjc3XzJIJwfGhicILveIVqdiCjbnSgcXJPSSCuZY\lcJMhd2ZiRWLDR\|EhcW5icHHjcIl1[XinbD3lfJBwe2WmwrDj[Yxtew>?	MnvqNlMzOjh4OU[=
H1650	M{PVemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYOxNOKh\|ryPwrC=	NY\M[4sxOSCq	M2LHNGROW09?	NUfCZ\|ky\W6qYX7j[ZMheGGlbHn0ZZhmdC2rbnT1Z4VlKGO7dH;0c5hq[2m2eR?=	M4LqVFI{OjJ6Nkm2
H1703	NU\4NpM6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWXCWGNPOTEEoN88UeKh	M2PtVlEhcA>?	NVHxfG15TE2VTx?=	MW\lcohidmOnczDwZYNtcXSjeHXsMYlv\HWlZXSgZ5l1d3SxeHnjbZR6	MmnZNlMzOjh4OU[=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	mTOR / p-S6K / S6K / p-S6 / p-AKT / p-MK2; PubMed: 26844273 EBioMedicine CRC cells were treated with 10 μM SB202190 for 2 h and analyzed for mTOR signaling and on-target inhibition of p38 by immunoblot. pJNK1 / pJNK2 / JNK1 / JNK2 ; PubMed: 18222647 Cell Signal A549 cells were treated with DMSO control or with 10 µM of SB202190 for 0.5, 1, 2, 3, 4, or 6 hours, and pJNK and unphosphorylated JNK were detected as described.	26844273 18222647
Immunofluorescence	p-p38 / MMP9; PubMed: 24479681 Mol Cancer Immunocytochemical staining and confocal microscopy confirmed that IL-1β increased activation of p38 (red), and MMP2 and MMP9 (green) expression in MKN-45 GA cells; these effects were blocked by p38 siRNA or the p38 inhibitor SB202190.	24479681
Growth inhibition assay	Cell viability ; PubMed: 26844273 EBioMedicine Top panel: CRC cells were treated with various concentrations of SB202190 for 48 h. Lower panel: CRC cells were treated with SB202190 at 10 μM for different times. Cell growth was measured by SRB assay (means ± s.d. in triplet, n = 3 in triplet).	26844273

体内研究

SB 202190通过抑制p38减弱了由人脊髓灰质炎IgG（PV-IgG）在被动转移小鼠模型中诱发的水泡形成^[5]。在脓毒症内毒素模型中，与对照组相比，经SB 202190处理可显著提高存活率^[8]。

激酶实验： ^[1]	- 合并体外酶活检测: p38α 和 p38β 溶解在25mM的Tris - HCl缓冲液中，PH 7.5，含0.1mM EGTA，髓鞘碱性蛋白（0.33毫克/毫升）作为底物。人工操作条件用50μL [γ-³³P]ATP于30 °C孵育10分钟；Biomek 2000自动化工作站用25μL [γ-³³P]ATP在96孔板室温孵育40分钟。ATP和乙酸镁浓度分别为0.1mM和10mM。所有检测都用MgATP起始。人工检测将孵育液滴到磷酸纤维素纸上，浸泡在50mM磷酸中。用5μL磷酸终止反应，后将孵育液点滴在P30过滤垫上。滤膜在50mM磷酸中漂洗四次以去除ATP，在用丙酮（人工孵育）或甲醇（工作站孵育）处理后，干燥并用放射性计量。
细胞实验： ^[2]	- 合并 Cell lines: Jurkat, 和 HeLa细胞 Concentrations: 溶解于DMSO, 终浓度~50 μM Incubation Time: 24 小时 Method: 细胞血清饥饿后，用不同浓度SB 202190处理24小时。用台盼蓝或PI染色后经流式细胞仪分析，以检测细胞活力。凋亡细胞核用H33258染色。 (Only for Reference)
动物实验： ^[5]	- 合并 Animal Models: C57BL/6J 小鼠皮内注射无菌的对照IgG或人脊髓灰质炎IgG做对比。 Dosages: 12.5 μg Administration: 皮内注射 (Only for Reference)

参考文献

- 合并

溶解度 (25°C)

体外	DMSO	66 mg/mL (199.19 mM)
	Ethanol	12 mg/mL (36.21 mM)
	Water	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 5%DMSO+40%PEG300+5%Tween80+50%H2O	8 mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download SB202190 (FHPI) SDF

分子量	331.34
化学式	C₂₀H₁₄N₃OF
CAS号	152121-30-7
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

p38 MAPK Signaling Pathway Map

p38 MAPK Inhibitors with Unique Features

选择性强的p38 MAPK抑制剂

BIRB 796 (Doramapimod) : p38α-selective, Kd=0.1 nM.
活性最高的p38 MAPK抑制剂

Skepinone-L ^New : p38α-MAPK, IC50=5 nM.
用于临床的p38 MAPK抑制剂

VX-702 : Phase II for Rheumatoid Arthritis.
最新的p38 MAPK抑制剂

Skepinone-L ^New : Selective p38α-MAPK inhibitor with IC50 of 5 nM.

研究领域

产品类型

定制您的化合物库

SB202190 (FHPI)

客户使用Selleck生产的SB202190 (FHPI)发表文献99篇：

产品安全说明书

p38 MAPK抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download SB202190 (FHPI) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

技术支持

p38 MAPK Signaling Pathway Map

p38 MAPK Inhibitors with Unique Features

相关p38 MAPK产品